Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients.

Oshima M, Deitiker PR, Jankovic J, Duane DD, Aoki KR, Atassi MZ.

J Neuroimmunol. 2011 Aug 15;237(1-2):66-72. doi: 10.1016/j.jneuroim.2011.06.005. Epub 2011 Jul 6.

PMID:
21737146
2.

Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.

Oshima M, Deitiker PR, Jankovic J, Duane DD, Aoki KR, Atassi MZ.

J Neuroimmunol. 2011 Dec 15;240-241:121-8. doi: 10.1016/j.jneuroim.2011.10.005. Epub 2011 Nov 12.

PMID:
22079193
3.

Evaluation of specific immune responses to BoNT/A and tetanus toxoid in patients undergoing treatment for neurologic disorders.

Vlata Z, Tsatsakis A, Tzagournissakis M, Krambovitis E.

Endocr Metab Immune Disord Drug Targets. 2012 Sep;12(3):268-73.

PMID:
22385115
6.

Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.

Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ.

Mol Immunol. 2007 Feb;44(5):1029-41. Epub 2006 May 2.

PMID:
16647121
7.

Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.

Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, Jankovic J.

Toxicon. 2013 Jun 1;67:94-114. doi: 10.1016/j.toxicon.2012.12.004. Epub 2013 Feb 4. Review.

PMID:
23380701
8.

Botulinum toxin versus submandibular duct relocation for severe drooling.

Scheffer AR, Erasmus C, VAN Hulst K, VAN Limbeek J, Rotteveel JJ, Jongerius PH, van den Hoogen FJ.

Dev Med Child Neurol. 2010 Nov;52(11):1038-42. doi: 10.1111/j.1469-8749.2010.03713.x.

9.

Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients.

Oshima M, Deitiker P, Jankovic J, Atassi MZ.

J Neuroimmunol. 2016 Nov 15;300:36-46. doi: 10.1016/j.jneuroim.2016.09.013. Epub 2016 Sep 29.

PMID:
27806874
10.

The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule.

Oshima M, Deitiker P, Jankovic J, Atassi MZ.

Immunol Invest. 2017 Sep 11:1-22. doi: 10.1080/08820139.2017.1368544. [Epub ahead of print]

PMID:
28891721
11.

Regions recognized on the light chain of botulinum neurotoxin type A by T lymphocytes of SJL and BALB/c mice primed with inactivated toxin.

Oshima M, Aoki KR, Atassi MZ.

Immunobiology. 2014 Dec;219(12):950-7. doi: 10.1016/j.imbio.2014.07.019. Epub 2014 Aug 7.

PMID:
25151501
12.

Ca2+ or Sr2+ partially rescues synaptic transmission in hippocampal cultures treated with botulinum toxin A and C, but not tetanus toxin.

Capogna M, McKinney RA, O'Connor V, Gähwiler BH, Thompson SM.

J Neurosci. 1997 Oct 1;17(19):7190-202.

13.
14.

Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients.

Oshima M, Deitiker P, Jankovic J, Aoki KR, Atassi MZ.

Immunobiology. 2016 Apr;221(4):568-76. doi: 10.1016/j.imbio.2015.12.002. Epub 2015 Dec 8.

PMID:
26701846
15.

Intramuscular pressure before and after botulinum toxin in chronic exertional compartment syndrome of the leg: a preliminary study.

Isner-Horobeti ME, Dufour SP, Blaes C, Lecocq J.

Am J Sports Med. 2013 Nov;41(11):2558-66. doi: 10.1177/0363546513499183. Epub 2013 Aug 22.

PMID:
23969633
16.

Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.

Frevert J.

Drugs R D. 2010;10(2):67-73. doi: 10.2165/11584780-000000000-00000.

17.
18.

Botulinum toxin in the treatment of rare head and neck pain syndromes: a systematic review of the literature.

Sycha T, Kranz G, Auff E, Schnider P.

J Neurol. 2004 Feb;251 Suppl 1:I19-30. Review.

PMID:
14991339
19.

Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins.

Kukreja R, Chang TW, Cai S, Lindo P, Riding S, Zhou Y, Ravichandran E, Singh BR.

Toxicon. 2009 May;53(6):616-24. doi: 10.1016/j.toxicon.2009.01.017.

PMID:
19673075
20.

Differences in the multiple step process of inhibition of neurotransmitter release induced by tetanus toxin and botulinum neurotoxins type A and B at Aplysia synapses.

Poulain B, De Paiva A, Deloye F, Doussau F, Tauc L, Weller U, Dolly JO.

Neuroscience. 1996 Jan;70(2):567-76.

PMID:
8848160

Supplemental Content

Support Center